South Korea · Delayed Price · Currency is KRW Livsmed Statistics
Total Valuation
Livsmed has a market cap or net worth of KRW 1.03 trillion. The enterprise value is 926.42 billion.
| Market Cap | 1.03T |
| Enterprise Value | 926.42B |
Important Dates
The next estimated earnings date is Friday, August 14, 2026.
| Earnings Date | Aug 14, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Livsmed has 24.95 million shares outstanding. The number of shares has increased by 26.89% in one year.
| Current Share Class | 24.95M |
| Shares Outstanding | 24.95M |
| Shares Change (YoY) | +26.89% |
| Shares Change (QoQ) | +10.70% |
| Owned by Insiders (%) | 39.07% |
| Owned by Institutions (%) | 13.42% |
| Float | 13.51M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 19.92 |
| PB Ratio | 5.90 |
| P/TBV Ratio | 5.96 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 17.91 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.99, with a Debt / Equity ratio of 0.07.
| Current Ratio | 10.99 |
| Quick Ratio | 9.83 |
| Debt / Equity | 0.07 |
| Debt / EBITDA | n/a |
| Debt / FCF | -0.27 |
| Interest Coverage | -29.61 |
Financial Efficiency
Return on equity (ROE) is -20.95% and return on invested capital (ROIC) is -12.94%.
| Return on Equity (ROE) | -20.95% |
| Return on Assets (ROA) | n/a |
| Return on Invested Capital (ROIC) | -12.94% |
| Return on Capital Employed (ROCE) | -13.34% |
| Weighted Average Cost of Capital (WACC) | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | n/a |
| Employee Count | n/a |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
| Beta (5Y) | n/a |
| 52-Week Price Change | n/a |
| 50-Day Moving Average | 60,408.00 |
| 200-Day Moving Average | n/a |
| Relative Strength Index (RSI) | 33.23 |
| Average Volume (20 Days) | 391,581 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Livsmed had revenue of KRW 51.72 billion and -22.46 billion in losses. Loss per share was -979.37.
| Revenue | 51.72B |
| Gross Profit | 28.05B |
| Operating Income | -24.35B |
| Pretax Income | -22.46B |
| Net Income | -22.46B |
| EBITDA | -21.24B |
| EBIT | -24.35B |
| Loss Per Share | -979.37 |
Balance Sheet
The company has 116.46 billion in cash and 12.30 billion in debt, with a net cash position of 104.16 billion or 4,174.01 per share.
| Cash & Cash Equivalents | 116.46B |
| Total Debt | 12.30B |
| Net Cash | 104.16B |
| Net Cash Per Share | 4,174.01 |
| Equity (Book Value) | 174.79B |
| Book Value Per Share | 7,017.88 |
| Working Capital | 152.26B |
Cash Flow
In the last 12 months, operating cash flow was -38.59 billion and capital expenditures -7.56 billion, giving a free cash flow of -46.15 billion.
| Operating Cash Flow | -38.59B |
| Capital Expenditures | -7.56B |
| Depreciation & Amortization | 3.11B |
| Net Borrowing | -828.50M |
| Free Cash Flow | -46.15B |
| FCF Per Share | -1,849.49 |
Margins
Gross margin is 54.22%, with operating and profit margins of -47.08% and -43.42%.
| Gross Margin | 54.22% |
| Operating Margin | -47.08% |
| Pretax Margin | -43.42% |
| Profit Margin | -43.42% |
| EBITDA Margin | -41.06% |
| EBIT Margin | -47.08% |
| FCF Margin | n/a |
Dividends & Yields
Livsmed does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -26.89% |
| Shareholder Yield | -26.89% |
| Earnings Yield | -2.18% |
| FCF Yield | -4.48% |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Livsmed has an Altman Z-Score of 45.67.
| Altman Z-Score | 45.67 |
| Piotroski F-Score | n/a |